Anyone else planning to buy themselves xmas shares !That was then ! Apeil 27 2023 ! Results have continues to improve from this latest Uddin report. Anyhow here is hoping we get some positive news in the comming weeks. Vaccine results to date overdue based on previous stated timeline IMHO.
Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given updated data released in the fourth quarter report in addition to compelling data released during the ASCO GU Cancer Symposium.
“We believe Ruvidar has the potential to achieve a better and longer duration of complete response (CR) than Merck’s Keytruda,” writes analyst Andre Uddin.
He said Ruvidar has a 43% complete response rate over 12 months across 21 evaluable patients (67% CR at day 450 for 12 patients), while Keytruda had a 19% CR across all 96 patients over 12 months.
Mr. Uddin reiterated a “speculative buy” rate for the stock and 80-cent price target.
Research Capital remains bullish of Theralase’s Ruvidar in NMIBC after new data - BioTuesdays